Catalent's stock down after Sarepta’s PhIII Duchenne study misses primary endpoint
Catalent’s stock $CTLT has dropped by as much as 17% to $33 on the Nasdaq after Sarepta announced on Monday that its Duchenne muscular …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
